Esperion Therapeutics, Inc. drugs

2 results
  • nexletol

    (Bempedoic Acid)
    Esperion Therapeutics, Inc.
    NEXLETOL is indicated for adults at risk of myocardial infarction and coronary revascularization who cannot take statins, and for reducing LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, either as a standalone treatment or with other LDL-C lowering therapies.
  • nexlizet

    (Bempedoic Acid and Ezetimibe)
    Esperion Therapeutics, Inc.
    NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated as an adjunct to diet for reducing LDL-C in adults with primary hyperlipidemia, including HeFH. Bempedoic acid also lowers myocardial infarction and coronary revascularization risk in adults unable to take statins, with or without established cardiovascular disease.